Want to see JYNT full AI Analyst Report?
JYNT Stock Chart & Stats
$9.22
$0.12(1.11%)
At close: 4:00 PM EST
$9.22
$0.12(1.11%)
Day’s Range― - ―
52-Week Range$7.50 - $11.79
Previous CloseN/A
Volume11.07K
Average Volume (3M)133.85K
Market Cap
$131.29M
Enterprise Value$110.62M
Total Cash (Recent Filing)$21.43M
Total Debt (Recent Filing)$2.04M
Price to Earnings (P/E)40.9
Beta1.14
Next Earnings
Aug 06, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.23
Shares Outstanding14,255,396
10 Day Avg. Volume93,155
30 Day Avg. Volume133,848
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)8.77
Price to Sales (P/S)2.40
P/FCF Ratio394.27
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue1.95
Enterprise Value/Gross Profit2.44
Enterprise Value/Ebitda37.58
Forecast
1Y Price Target
$10.50Price Target Upside13.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.28
Revenue Forecast (FY)$60.29M
Bulls Say, Bears Say
Bulls Say
High Gross Margin And Cash GenerationA sustained ~78.5% gross margin reflects strong unit economics from a franchise-oriented service model, enabling high contribution per visit. Coupled with improved TTM free cash flow (~$2.7M), this supports durable cash generation to fund reinvestment, buybacks, and franchise growth even if operating leverage ramps slowly.
Near-complete Refranchising To Asset-light ModelConverting most company-owned clinics into franchised units is a structural shift to an asset-light franchisor. This reduces capex and operating costs, concentrates earnings into recurring royalties and fees, and should sustainably improve adjusted EBITDA margins and free cash flow conversion as the model scales and corporate G&A normalizes.
Low Leverage And Stronger Liquidity PostureLow and improving leverage (debt/equity ~0.13) plus an extended, undrawn revolving facility gives the company durable balance-sheet flexibility. That cushioning lowers refinancing risk, preserves capacity for strategic actions (refranchising, marketing, targeted buybacks), and supports steady execution through multi-quarter transitions.
Bears Say
Very Thin Operating ProfitabilityWith an EBIT margin near 0.2%, the business has minimal operating cushion to absorb revenue shortfalls or unexpected costs. Even modest declines in system-wide or comparable sales can quickly eliminate operating profits, increasing sensitivity to execution delays in refranchising, marketing effectiveness, or pricing rollouts.
Multi-year Earnings And Cash-flow VolatilityHistoric swings into losses in 2023–2024 and inconsistent free cash flow undermine predictability. This volatility raises risk that pro-forma margins and FCF conversion targets may not be realized on schedule, complicating capital allocation and making sustained investment or share repurchases more uncertain over the next several quarters.
Execution And Timing Risk Tied To Comps And RefranchisingNear-term recovery depends on multiple coordinated initiatives—national marketing, SEO/AI gains, pricing rollout and completion of lease assignments—creating execution and timing risk. Delays or weaker-than-expected comp recovery would limit royalty growth and defer the anticipated margin and cash-flow benefits from refranchising.
Joint News
JYNT FAQ
What was Joint Corp’s price range in the past 12 months?
Joint Corp lowest stock price was $7.50 and its highest was $11.79 in the past 12 months.
What is Joint Corp’s market cap?
Joint Corp’s market cap is $131.29M.
When is Joint Corp’s upcoming earnings report date?
Joint Corp’s upcoming earnings report date is Aug 06, 2026 which is in 26 days.
How were Joint Corp’s earnings last quarter?
Joint Corp released its earnings results on May 07, 2026. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.033 by $0.047.
Is Joint Corp overvalued?
According to Wall Street analysts Joint Corp’s price is currently Undervalued.
Does Joint Corp pay dividends?
Joint Corp does not currently pay dividends.
What is Joint Corp’s EPS estimate?
Joint Corp’s EPS estimate is 0.05.
How many shares outstanding does Joint Corp have?
Joint Corp has 14,255,396 shares outstanding.
What happened to Joint Corp’s price movement after its last earnings report?
Joint Corp reported an EPS of $0.08 in its last earnings report, beating expectations of $0.033. Following the earnings report the stock price went up 0.231%.
Which hedge fund is a major shareholder of Joint Corp?
Currently, no hedge funds are holding shares in JYNT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Joint Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.50 (13.88% Upside)
$10.50 (13.88% Upside)
Insider Transactions
Bought Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.36%
12-Months-Change
Fundamentals
Return on Equity
16.94%
Trailing 12-Months
Asset Growth
-27.68%
Trailing 12-Months
Company Description
Joint Corp
The Joint Corp. specializes in the establishment, proprietorship, operation, and overall administration of chiropractic treatment centers. Its business operations are structured into two main divisions: corporate-owned clinics and franchised facilities. The firm employs several strategic models for its expansion and day-to-day functioning, which include direct company ownership, various management agreements, licensing its brand to franchisees, and collaborating with regional development partners. As of March 1, 2022, the company maintained approximately 700 active locations throughout the United States. Founded in 2010, The Joint Corp. maintains its primary corporate headquarters in Scottsdale, Arizona.
JYNT Company Deck
JYNT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights a clear operational and financial inflection driven by near-complete refranchising: revenue growth from continuing operations (+13%), substantial adjusted EBITDA improvement, a return to net income, and disciplined capital allocation (share repurchases and RD buybacks). Management acknowledges near-term headwinds with system-wide sales and comps down (~-4.9% and -4.2% respectively) and some transitional G&A and cash reductions, but provides concrete actions (pricing rollout, marketing, SEO/AI gains, CareCredit, B2B initiatives) and reiterated full-year guidance with a compelling pro-forma margin profile. Overall, the positives from the transformation, profitability gains, and strategic initiatives outweigh the current softness in comps and cash timing risks, supporting an upbeat outlook as refranchising closes and H2 initiatives ramp.View all JYNT earnings summariesJYNT Stock 12 Month Forecast
Average Price Target
$10.50
▲(13.88% Upside)
Technical Analysis
Ownership Overview
14.81% Insiders
13.36% Mutual Funds
44.43% Other Institutional Investors
21.86% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---